I've got a fun startup panel, so join me at STAT Breakthrough Summit West next month!

statnews.com/2024-breakthro…

Welp they finally found a way to suck the joy out of coffee so it’s been fun I guess

Hey, I know this guy!

Pleased that Zachary Tracer is joining us at STAT. And Rachel Cohrs Zhang will be a wonderful leader on our DC team.
statnews.com/new-leadership…

Exclusive: Spark Therapeutics cofounder Steven Altschuler has a new startup focused on making vaccines for cancer, influenza, and potentially even HIV. STAT got a first look:

statnews.com/2024/04/18/can…

A new biotech backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development.

statnews.com/2024/04/18/met…

Bob Herman and Casey Ross — or “Bob Ross,” as we now refer to them in the STAT newsroom — deserve this for their truly stellar reporting.

This is a great award honoring a great science journalist. (Deadline 4/30) Sharon Begley Science Reporting Award - CASW casw.org/awards-fellows…

$ITCI Intra-Cellular reports positive results in depression study aimed at expanding use of antispsychotic medicine statnews.com/2024/04/16/int…

Yayyy!! Looking forward to working even more closely with Elaine Chen

A VERY special episode of the Readout LOUD with a SHOCKING ending...

Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson statnews.com/2024/04/11/rea… via STAT

Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond what Wall Street or even the drug’s manufacturer has projected — according to a document obtained by STAT.

statnews.com/2024/04/11/med…

So I guess we know the last time I wore this jacket…

Seaport debuts with $100M Series A, as psychiatric boom grows statnews.com/2024/04/09/sea…

The numbers are in!

Privately held biotech startups recently closed out their best fundraising quarter in two years, signaling that the industry downturn may soon be a thing of the past.

statnews.com/2024/04/09/bio…

I can’t see how these kinds of drug approvals won’t become key issues to the field in the years to come. Experts are already questioning cancer drugs that halt tumor growth but don’t extend survival.

The study by WHO scientists suggests the number of late-stage cancers, the endpoint in Grail's trials of its cancer liquid biopsy, is insufficient to show the Galleri test benefits patients. statnews.com/2024/04/07/gra… via STAT

I’m in Atlanta for #ACC24 ! Sign up for our newsletter— I’ll be covering the new data coming out each day:
statnews.com/signup/acc-30-…

the first story from STAT's inaugural disability reporting fellow Timmy Broderick is here! read it! on how few people who are eligible for cochlear implants actually get them, and on how access is even worse for certain marginalized populations: statnews.com/2024/04/04/coc…

Amylyx to pull ALS drug from market, cut 70% of staff statnews.com/2024/04/04/amy… via STAT Allison DeAngelis

.Elaine Chen has the breakdown of new study results on an older GLP-1 diabetes drug called lixisenatide.